Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) was the target of a significant decrease in short interest during the month of October. As of October 30th, there was short interest totaling 3,236,659 shares, a decrease of 46.9% from the October 15th total of 6,094,189 shares. Currently, 5.9% of the shares of the company are sold short. Based on an average trading volume of 1,127,185 shares, the short-interest ratio is currently 2.9 days.
Wall Street Analysts Forecast Growth
A number of research firms have issued reports on TARA. Wall Street Zen raised shares of Protara Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Saturday, September 5th. Weiss Ratings restated a "sell (d-)" rating on shares of Protara Therapeutics in a research report on Thursday, October 15th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Protara Therapeutics in a research note on Thursday, October 15th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $26.25.
Get Our Latest Report on TARA
Protara Therapeutics Stock Performance
NASDAQ:TARA opened at $2.53 on Monday. The stock has a market cap of $155.77 million, a price-to-earnings ratio of -1.82 and a beta of 1.54. Protara Therapeutics has a 1 year low of $2.09 and a 1 year high of $7.82. The business has a fifty day moving average of $2.89 and a 200-day moving average of $4.39.
Protara Therapeutics (NASDAQ:TARA - Get Free Report) last issued its quarterly earnings data on Friday, November 6th. The company reported ($0.35) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.02. On average, equities research analysts predict that Protara Therapeutics will post -1.37 EPS for the current year.
Hedge Funds Weigh In On Protara Therapeutics
Several large investors have recently bought and sold shares of TARA. Corient Private Wealth LP bought a new stake in shares of Protara Therapeutics during the 2nd quarter worth about $41,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Protara Therapeutics by 22.2% in the first quarter. The Manufacturers Life Insurance Company now owns 13,548 shares of the company's stock valued at $71,000 after acquiring an additional 2,464 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Protara Therapeutics in the second quarter valued at approximately $69,000. Public Employees Retirement System of Ohio bought a new position in shares of Protara Therapeutics in the second quarter valued at approximately $113,000. Finally, WINTON GROUP Ltd increased its stake in shares of Protara Therapeutics by 16.7% during the second quarter. WINTON GROUP Ltd now owns 32,800 shares of the company's stock valued at $125,000 after acquiring an additional 4,700 shares during the period. Institutional investors and hedge funds own 38.13% of the company's stock.
About Protara Therapeutics
(
Get Free Report)
Protara Therapeutics is a clinical-stage biotechnology company developing treatments for cancer and rare diseases. Its programs are investigational and are not approved for general use. The company's lead program, TARA-002, is a cell-based immunotherapy being studied for non-muscle invasive bladder cancer and lymphatic malformations. Protara is also developing intravenous choline chloride for people with intestinal failure-associated liver disease. Protara was formed in 2019 through a merger involving ArTara Therapeutics.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Protara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protara Therapeutics wasn't on the list.
While Protara Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.